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Modern continuous-flow ventricular assist devices (VADs) have greatly improved
the survival of patients with end stage heart failure. However, they are associated
with adverse effects, including cerebrovascular accidents (CVA), bleeding,
infection, and device thrombosis. Definitive measures to evaluate for pump
thrombosis can be challenging; hence, multiple laboratory and imaging modalities
have been studied to help guide decision making. Lactate dehydrogenase (LDH)
has proven to be a reliable test when used in the appropriate clinical settings to
help diagnose pump thrombosis. When a patient presents with both signs of lifethreatening cerebral hemorrhage and VAD thrombosis, the clinical picture can be
quite challenging. We present a case with intracerebral hemorrhage that was
associated with a significant increase in LDH and created a clinical dilemma since
anticoagulation had to be completely reversed in the setting of the bleed. The fact
that brain injury (in particular hemorrhage) leads to elevation of LDH is highlighted.
Importantly, not all that raises LDH in a ventricular assist patient is thrombosis of
the device.
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Background
Modern continuous-flow ventricular assist devices (VADs) have greatly improved
the survival of patients with end stage heart failure. However, they are associated
with adverse effects, including cerebrovascular accidents (CVA), bleeding,
infection, and device thrombosis. Definitive measures to evaluate for pump
thrombosis can be challenging; hence multiple laboratory and imaging modalities
have been studied to help guide decision making. Lactate dehydrogenase (LDH)
has proven to be a reliable test when used in the appropriate clinical settings to
help diagnose pump thrombosis. When a patient presents with both signs of lifethreatening cerebral hemorrhage and VAD thrombosis, the clinical picture can be
quite challenging.

Case Report
A 62-year-old male received a HeartMate II VAD (Abbott) four years prior to
admission and was currently listed for a heart transplant. He presented to the
emergency department following the acute onset of slurred speech. Computed
tomography (CT) of the head showed a 1.4 cm left frontal lobe hemorrhage with
subarachnoid extension. Laboratory data on arrival are listed in Table 1. Of note,
LDH was 2.2 times the upper limit of the normal range.

Table 1. Admission laboratory values
Hemoglobin
Platelets
Plasma-free hemoglobin
International normalized ratio
Lactate dehydrogenase
Creatinine
Total bilirubin

11.1 g/dL
106 K/µL
4.5 mg/dL (normal range: 0-4.9 mg/dl)
3.5
426 U/L, (normal range 98-192)
1.2 mg/dL
0.8 mg/dL

Neurosurgery recommended the immediate reversal of warfarin and, in the short
term, no further anticoagulant. The patient’s dysarthria improved, and he was
admitted to the neurology intensive care unit for ongoing monitoring. An
echocardiogram demonstrated appropriate VAD function with a closed aortic valve
and normal VAD inflow velocities.
The following day, a repeat head CT demonstrated expansion of the left frontal
lobe bleed to 2.2 cm despite the reversal of anticoagulation and cessation of
antiplatelet agents. LDH levels sharply climbed along with other markers of VAD
thrombosis (Figure 1). The plasma free hemoglobin rose from 4.5 mg/dL to 42
mg/dL, and haptoglobin was undetectable. LDH isoenzyme fractionation was
obtained on a peak value of 936 (upper limit of normal 224, 4.2 times upper limit):
LDH-1: 35 % [17-32%], LDH- 2: 35% [25-40%], LDH-3: 19 % [17-27%], LDH-4:
5% [5-13%], LDH-5: 6 % [4-20].
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Figure 1. Total serum lactase dehydrogenase levels throughout the hospital stay.

Given the acute hemorrhagic CVA, the patient was not a candidate for an urgent
transplant nor VAD pump exchange. The team was concerned that the patient had
evolving VAD thrombosis, and if so, we needed to counsel the patient that this was
likely a terminal event. After reviewing the LDH fractionation, we realized that the
LDH could have been driven by his cerebral bleed, and we were able to watch
without anticoagulation despite multiple indices pointing towards VAD thrombosis.
The VAD parameters remained normal, and the patient remained asymptomatic.
On hospital day 5, warfarin therapy was re-initiated with a lower target international
normalized ratio of 1.5-2, and the patient was monitored closely. He remained
hemodynamically stable and was successfully discharged to home on hospital day
11. On the day of discharge, his LDH was 442 U/L, but the remainder of his labs
continued to be within a normal range. Two weeks later, a repeat head CT scan
showed interval improvement in the size of his hemorrhagic foci without evidence
of extension.

Discussion
LDH has a tetrameric structure, with subunits most commonly made up of LDH-H
and LDH-M proteins, which can, in turn, form five possible pentamers or
isoenzymes of LDH with different concentrations in different tissues.1 Of these,
LDH-1 is localized primarily in the brain, the heart, and in red blood cells. LDH-2,
the predominant form in the serum, is localized primarily to the reticuloendothelial
system. LDH-3 is localized in the lungs. LDH-4 localizes in the pancreas and renal
system, and LDH-5 is found in striated muscle and the liver.1 Little has been
previously reported on the kinetics of LDH-1 within the neuron. One previous in
vitro study on human LDH-1 isoenzyme reported an average half-life of
approximately 110 hours in the absence of other physiological stressors.1
In patients with acute ischemic or hemorrhagic strokes and no evidence of
concurrent cardiac lesions, serum LDH has been previously shown to rise in
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proportion with the cardiac-specific enzymes aspartate aminotransferase (AST)
and creatine phosphokinase myocardial band (CPK-MB); where the sharpest
increases in LDH, AST, and CPK-MB were seen in patients with hemorrhagic
CVA.2 Further, all three proteins follow similar expression profiles, with peaks at
approximately post-stroke day 4, suggesting the concurrent existence of acute
myocardial dysfunction in some patients with acute intracranial hemorrhage (ICH).2
Changes in serum LDH levels have been correlated previously with intravascular
hemolysis and pump thrombosis in patients with continuous-flow LVAD support.3,4
In appropriate clinical settings, studies have shown a rise of 2.5 times or greater
from total baseline LDH is indicative of pump thrombosis.3,4
The current case illustrates that intracranial bleeding may lead to marked
elevations of serum LDH, which may confound the clinical picture for patients on
VAD support who have frequent monitoring of LDH.
In patients with acute hemorrhagic CVAs, an increased total serum LDH level may
serve as an independent and reliable predictor of hematoma expansion.5-7 In
conjunction with imaging to evaluate for ICH, the changes in serum LDH levels
may have significant predictive value in guiding the decision of when to resume
anticoagulation in a patient with an acute CVA as well as a VAD, as was seen in
this case.5-7
The current case illustrates a patient with dramatic elevations of VAD thrombosis
markers with a HeartMate II VAD, and yet the patient never required a pump
exchange. The brain bleed was the likely culprit for the blood test abnormalities,
and the correct course of action was patience and supportive care.
Since both brain and red blood cell damage affect LDH-1, the value of fractionating
the LDH is to exclude other causes such as lung (LDH-3) or skeletal muscle (LDH5). In the case of a patient unfortunate enough to have a brain injury and a VAD
thrombosis, the LDH-1 would be elevated, and clinical judgment and
hemodynamic/echocardiographic data would guide diagnosis and management.
On the other hand, a patient with severe pneumonia, or high CPK with
rhabdomyolysis could also have a very high LDH and yet have no issues with their
VAD. As cardiologists, we tend to focus on the risk of VAD thrombosis when noting
a high serum LDH. However, it is important to know the other origins of these
enzyme elevations, and fractionation can help establish the source.
In summary, this report highlights the fact that intracranial pathology can lead to
marked elevations of serum LDH and mimic incipient VAD thrombosis.
Fractionation of LDH can be helpful, but ultimately, clinical judgment is the best
way to decide if rising enzymes signify a damaged pump, damaged brain, or both.
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